Alternative Clinical Approaches and Data for Patients not Suitable for 2L CAR T
Panelists discuss treatment options for patients ineligible for chimeric antigen receptor T-cell therapy in the second-line setting, focusing on the selection of new proteasome inhibitors and/or immune-mediated immunomodulatory drugs vs recycling combination regimens, and reviewing recent data from the APOLLO and IKEMA trials that support the use of combination therapies in relapsed/refractory multiple myeloma.
Video content above is prompted by the following:
- For patients not suitable to receive chimeric antigen receptor T-cell therapy in the second line, what current/emerging treatments would you consider?
- How do you approach selecting a new proteasome inhibitor and/or immune-mediated immunomodulatory drug vs recycling a combination regimen?
- Briefly comment on recent data in combination regimens that support their use:
- APOLLO trial, DPd vs Pd in patients with relapsed/refractory multiple myeloma (R/R MM)
- IKEMA trial, Isa-Kd vs Kd in patients with R/R MM
Recent Videos
Related Content
